Mario Mandalà

33PUBLICATIONS
176CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|May 04, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

|Apr 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Jan 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Reinhard Dummer, Shibing Deng, Tao Xie

|Oct 21, 2025
Evaluation of Sonidegib Cytoreductive Activity in Locally Advanced Basal Cell Carcinoma Treatment: A Delphi Consensus.

Paolo Antonio Ascierto, Maria Concetta Fargnoli, Corrado Caracò

|Sep 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Georgina V Long, Nitya Nair, Daniel Marbach

Pageof 6

Frequent Collaborators

16 joint publications

Paolo Antonio Ascierto

8 joint publications

Helen J Gogas

7 joint publications

Ana M Arance Fernandez

7 joint publications

Reinhard Dummer